Qube Research & Technologies (QRT)’s TG Therapeutics TGTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,448	Closed	-$1.06M	–	4126
2025 Q4	$1.06M	Buy	+35,448	New	+$1.16M	﹤0.01%	2537
2024 Q4	–	Sell	-371,841	Closed	-$8.7M	–	3819
2024 Q3	$8.7M	Buy	+371,841	New	+$8.12M	0.01%	1117
2024 Q2	–	Sell	-107,363	Closed	-$1.63M	–	4706
2024 Q1	$1.63M	Buy	+107,363	New	+$1.71M	﹤0.01%	1866
2023 Q1	–	Sell	-215,527	Closed	-$2.55M	–	3017
2022 Q4	$2.55M	Buy	215,527 +60,206	+39%	+$437K	0.01%	865
2022 Q3	$920K	Sell	155,321 -67,767	-30%	-$444K	0.01%	1237
2022 Q2	$948K	Buy	+223,088	New	+$1.39M	0.01%	1127
2021 Q3	–	Sell	-23,438	Closed	-$909K	–	2766
2021 Q2	$909K	Buy	+23,438	New	+$920K	0.01%	988
2020 Q3	–	Sell	-17,413	Closed	-$339K	–	2103
2020 Q2	$339K	Buy	+17,413	New	+$280K	0.01%	1250
2020 Q1	–	Sell	-23,095	Closed	-$256K	–	1655
2019 Q4	$256K	Buy	+23,095	New	+$176K	0.01%	1297

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Qube Research & Technologies (QRT)'s TGTX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 35,448 shares — an estimated $1.06M sold.

Qube Research & Technologies (QRT) first reported a position in TGTX in Q4 2019 and held it in 9 quarters. The position peaked at $8.7M in Q3 2024. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Qube Research & Technologies (QRT) reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 35,448 TG Therapeutics shares in Q1 2026, an estimated $1.06M.
Qube Research & Technologies (QRT) first reported a position in TG Therapeutics in Q4 2019 and held it in 9 quarters.
Qube Research & Technologies (QRT)'s TG Therapeutics position peaked at $8.7M in Q3 2024.
365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.